StockData

Alnylam Pharmaceuticals vs Sarepta Therapeutics

ALNY and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and SRPT compare

Alnylam Pharmaceuticals is the larger company, worth 13 times as much as Sarepta Therapeutics ($21.0B against $1.6B).

Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus −20.4% for Sarepta Therapeutics).

Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with −6.9% at Sarepta Therapeutics.

Sarepta Therapeutics scores higher on the StockData Score (12 against 10 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYSRPT
Size and price
Market cap$21.0B$1.6B
Share price$156.50$14.77
Change, 1 year−65.2%−21.5%
Change, 5 years−17.0%−81.4%
Beta (5Y)0.921.71
Employees2,500835
StockData Score
Total score1012 (better)
Valuation score33
Growth score2 (better)1
Performance score33
Health score25 (better)
Dividend score00
Valuation
P/E8.1×–
P/S4.2×0.8× (better)
P/B5.8×1.0× (better)
EV/EBITDA16.8×–
P/FCF26.0×19.1× (better)
FCF yield3.8%5.2% (better)
Fair value$296.91$106.96
Margin of safety47.3%86.2% (better)
Growth
Revenue growth (TTM)56.2% (better)−20.4%
Revenue growth, 5Y average49.8% (better)32.4%
Net income growth (TTM)2137%–
EPS growth (TTM)2308%–
Profitability
Gross margin77.4%–
Operating margin19.5% (better)−7.3%
Net margin52.8% (better)−6.9%
FCF margin16.1% (better)4.1%
Return on equity127% (better)−9.3%
Return on invested capital–−16.8%
Financial health
Debt / equity–0.00
Interest coverage3.2×–
Current ratio2.484.42 (better)
Altman Z-score3.62 (better)−0.32
Piotroski F-score6 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.7%102%
Held by insiders0.49%5.9%
Insider net buying, 12 months−$26.3M−$417K (better)
Short interest, % of float4.1%19.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.